Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Genitourinary 2Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Plasma cell 1Myeloid 1

Conditions

Liver Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × oblimersen × Gastrointestinal × Clear all
NCT00047229 2017-11-08

Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

University Health Network, Toronto

Phase 2 Completed
27 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00091078 2013-06-05

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
96 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡